Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 351-357

  Reddy, P ^a   Johnson, K ^b   Uberti, J P ^c   Reynolds, C ^a   Silver, S ^a   Ayash, L ^c   Braun, T M ^d   Ratanatharathorn, V ^c  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

GVHD; Kidneys; Nephrotic syndrome

Indexed keywords

B LYMPHOCYTE ANTIBODY; BUSULFAN; CARMUSTINE; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FATALITY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; IRRADIATION; KIDNEY BIOPSY; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LUNG ASPERGILLOSIS; MALE; MEDICAL RECORD REVIEW; MYELOFIBROSIS; MYELOMA; NEPHROTIC SYNDROME; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEINURIA; PUVA; REDUCED INTENSITY CONDITIONING; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT WITHDRAWAL;

ADULT; BIOPSY; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747373386     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705446     Document Type: Article

References (43)

1. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestation and therapy (Review) (126 refs). Hematopoietic Cell Transplant 2001; 28: 121-129.
2. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
3. Scott MA, Gandhi MK, Jestice HK, Mahendra P, Bass G, Marcus RE. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study. Hematopoietic Cell Transplant 1998; 22: 273-276.
4. Solano C, Martinez C, Brunet S, Tomas JF, Urbano-Ispizua A, Zuazu J et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or hematopoietic cell transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Hematopoietic Cell Transplant 1998; 22: 1129-1135.
5. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease (see comments). Blood 1997; 90: 4705-4709.
6. Urbano-Ispizua A, Garcia-Conde J, Brunet S, Hernandez F, Sanz G, Petit et al. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. Haematologica 1997; 82: 683-689.
7. Murphy WJ. Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes (comment). J Clin Invest 2000; 106: 745-747.
8. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading (Review) (11 refs). Hematopoietic Cell Transplant 1995; 15: 825-828.
10. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
11. Ratanatharathorn V, Karanes C, Lum LG, Uberti J, Dan ME, de Planque MM et al. Allogeneic hematopoietic cell transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Hematopoietic Cell Transplant 1992; 9: 49-55.
12. Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Hematopoietic Cell Transplant 2001; 27: 801-807.
13. Tutschka PJ, Copelan EA, Klein JP. Hematopoietic cell transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
14. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic hematopoietic cell transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
15. Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003; 9: 189-197.
16. Barbara JA, Thomas AC, Smith PS, Gillis D, Ho JO, Woodroffe AJ. Membranous nephropathy with graft-versus-host disease in a hematopoietic cell transplant recipient. Clin Nephrol 1992; 37: 115-118.
17. Gomez-Garcia P, Herrera-Arroyo C, Torres-Gomez A, Gomez-Carrasco J, Aljama-Garcia P, Lopez-Rubio F et al. Renal involvement in chronic graft-versus-host disease: A report of two cases. Hematopoietic Cell Transplant 1988; 3: 357-362.
18. Hiesse C, Goldschmidt E, Santelli G, Charpentier B, Machover D, Fries D. Membranous nephropathy in a hematopoietic cell transplant recipient. Am J Kidney Dis 1988; 11: 188-191.
19. Lin J, Markowitz GS, Nicolaides M, Hesdorffer CS, Appel GB, D'Agati VD et al. Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature (Review) (24 refs). Am J Nephrol 2001; 21: 351-356.
20. Muller GA, Muller CA, Markovic-Lipkowski J, Bross-Bach U, Schmidt H, Ehninger G et al. Membranous nephropathy after hematopoietic cell transplantation in ciclosporin treatment. Nephron 1989; 51: 555-556.
21. Nergizoglu G, Keven K, Ates K, Ustun C, Tulunay O, Beksac M et al. Chronic graft-versus-host disease complicated by membranous glomerulonephritis. Nephrol Dialysis Transplant 1999; 14: 2461-2463.
22. Ohsawa I, Ohi H, Fujita T, Endo M, Ito T, Sawada U et al. Glomerular and extraglomerular immune complex deposits in a hematopoietic cell transplant recipient. Am J Kidney Dis 2000; 36: E3.
23. Oliveira JS, Bahia D, Franco M, Balda C, Stella S, Kerbauy J. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. Hematopoietic Cell Transplant 1999; 23: 99-101.
24. Rossi L, Cardarelli F, Vampa ML, Buzio C, Olivetti G. Membranous glomerulonephritis after haematopoietic cell transplantation for multiple myeloma (Review) (18 refs). Nephron 2001; 88: 260-263.
25. Sato N, Kishi K, Yagisawa K, Kasama J, Karasawa R, Shimada H et al. Nephrotic syndrome in a hematopoietic cell transplant recipient with chronic graft-versus-host disease. Hematopoietic Cell Transplant 1995; 16: 303-305.
26. Yorioka N, Taniguchi Y, Shimote K, Komo T, Yamakido M, Hyodo H et al. Membranous nephropathy with chronic graft-versus-host disease in a hematopoietic cell transplant recipient (letter). Nephron 1998; 80: 371-372.
27. Shi Q, Wu MH, Fujita Y, Ishida A, Wijelath ES, Hammond WP et al. Genetic tracing of arterial graft flow surface endothelialization in allogeneic marrow transplanted dogs. Cardiovas Surg 1999; 7: 98-105.
28. Romagnani P, Lazzeri E, Mazzinghi B, Lassagni L, Guidi S, Bosi A et al. Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: Novel molecular diagnostic tools for a challenging differential diagnosis. Am J Kidney Dis 2005; 46: 550-556.
29. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
30. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
31. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-551.
32. Pan L, Delmonte JJ, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
33. Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629-1634.
34. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm (review) (172 refs). Immunol Res 1996; 15: 50-73.
35. Graze PR, Gale RP. Chronic graft versus host disease: A syndrome of disordered immunity. Am J Med 1979; 66: 611-620.
36. De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361-366.
37. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia (see comments). Blood 1989; 73: 1054-1058.
38. Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103: 353-359.
39. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-511.
40. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-2978.
41. Emerson SG. GVHD and relapse: To B or not to B. Blood 2005; 105: 2627-2628.
42. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275-279.
43. Seconi J, Watt V, Ritchie DS. Nephrotic syndrome following allogeneic stem cell transplantation associated with increased production of TNF-alpha and interferon-gamma by donor T cells. Bone Marrow Transplant 2003; 32: 447-450.